SciSparc (SPRC) Surges on Deal Nod; Co-Diagnostics (CODX) Rallies; Other Biotechs Draw Interest

Shares of SciSparc Ltd. (SPRC) leaped on May 29, 2026 after the company secured regulatory approval for a strategic transaction, while Co-Diagnostics Inc. (CODX) rallied sharply on upbeat financial news. Several other small-cap biotech firms, including Outlook Therapeutics (OTLK), Akari Therapeutics (AKTX), and Fortress Biotech (FTRE), also drew heavy investor attention, driving them among the day’s top gainers. SPRC surged over 25% in morning trade following confirmation that a key deal—details of which were not immediately disclosed—had received a green light from authorities. CODX advanced 18% after reporting a narrower-than-expected quarterly loss and lifting its full-year revenue forecast, citing growing demand for its diagnostic tools. OTLK, AKTX, and FTRE each rose by double-digit percentages without associated corporate announcements, as retail trading interest spiked. The broader biotech sector was mixed.